PfMFR3: A Multidrug-Resistant Modulator in .

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

ACS infectious diseases, Volume: 7, Issue: 4
April 9, 2021
Frances Rocamora F, Purva Gupta P, Eva S Istvan ES, Madeline R Luth MR, Emma F Carpenter EF, Krittikorn Kümpornsin K, Erika Sasaki E, Jaeson Calla J, Nimisha Mittal N, Krypton Carolino K, Edward Owen E, Manuel Llinás M, Sabine Ottilie S, Daniel E Goldberg DE, Marcus C S Lee MCS, Elizabeth A Winzeler EA

In malaria, chemical genetics is a powerful method for assigning function to uncharacterized genes. MMV085203 and GNF-Pf-3600 are two structurally related napthoquinone phenotypic screening hits that kill both blood- and sexual-stage parasites in the low nanomolar to low micromolar range. In order to understand their mechanism of action, parasites from two different genetic backgrounds were exposed to sublethal concentrations of MMV085203 and GNF-Pf-3600 until resistance emerged. Whole genome sequencing revealed all 17 resistant clones acquired nonsynonymous mutations in the gene encoding the orphan apicomplexan transporter PF3D7_0312500 () predicted to encode a member of the major facilitator superfamily (MFS). Disruption of and testing against a panel of antimalarial compounds showed decreased sensitivity to MMV085203 and GNF-Pf-3600 as well as other compounds that have a mitochondrial mechanism of action. In contrast, mutations in provided no protection against compounds that act in the food vacuole or the cytosol. A dihydroorotate dehydrogenase rescue assay using transgenic parasite lines, however, indicated a different mechanism of action for both MMV085203 and GNF-Pf-3600 than the direct inhibition of cytochrome bc1. Green fluorescent protein (GFP) tagging of PfMFR3 revealed that it localizes to the parasite mitochondrion. Our data are consistent with PfMFR3 playing roles in mitochondrial transport as well as drug resistance for clinically relevant antimalarials that target the mitochondria. Furthermore, given that is naturally polymorphic, naturally occurring mutations may lead to differential sensitivity to clinically relevant compounds such as atovaquone.

Courtesy of the U.S. National Library of Medicine